Watson Confirms Glumetza Patent Challenge

Watson Pharmaceuticals confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market metformin hydrochloride extended-release tablets USP, 1,000 mg. Watson’s metformin hydrochloride extended-release tablets are a generic version of Depomed’s Glumetza.
The Sacramento Bee